GENOSS Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 2004-02-25
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genoss.com
Clinical Trials
14
Active:2
Completed:5
Trial Phases
1 Phases
Not Applicable:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Not Applicable
5 (100.0%)The Safety and Efficacy for In-segment Late Lumen Loss of the 'Genoss® SCB' Versus 'SeQuent® Please NEO' in Patients With Coronary ISR
Not Applicable
- Conditions
- Coronary Arterial Disease (CAD)
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT07159087
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, South Korea
Safety and Efficacy of GENOSS® DCB With a Shellac Plus Vitamin E Excipient in Patients With De Novo Lesion
- Conditions
- Coronary Artery Disease(CAD)
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 3000
- Registration Number
- NCT07158307
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, South Korea
Efficacy and Safety of GENOSS SES in Patients With Coronary Artery Disease
Active, not recruiting
- Conditions
- Coronary Arterial Disease (CAD)
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1118
- Registration Number
- NCT06841510
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, South Korea
Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease
- Conditions
- Percutaneous Coronary InterventionMultivessel Coronary Artery Disease
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06168305
- Locations
- 🇰🇷
Korea University GURO Hospital, Seoul, Seoul, South Korea
Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent (GENOSS® DES)
- Conditions
- Coronary Artery DiseasePercutaneous Coronary Intervention
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Genoss Co., Ltd.
- Target Recruit Count
- 1000
- Registration Number
- NCT06086496
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Seoul, South Korea
- Prev
- 1
- 2
- 3
- Next
News
No news found